Paroxetine

Template:Short description Template:Use dmy dates Template:Cs1 config Template:Main other {{#invoke:Infobox|infobox}}Template:Template other{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= biosimilars= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= container_only= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= DTXSID= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= class6= component1= component2= component3= component4= component5= component6= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= image_class= image_class2= image_classL= image_classR= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_AU_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= DTXSID2= QID= QID2=PLLR= pregnancy_US= pregnancy_US_comment= |cat=Pages using infobox drug with unknown parameters |format=0|errNS=0

|preview=

}}{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals={{#invoke:ParameterCount |main |component1 |component2 |component3 |component4|component5|component6 }} | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=1920113c1cc(ccc1[C@@H]2CCNC[C@H]2COc3ccc4c(c3)OCO4)F1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1AHOUBRCZNHFOSL-YOEHRIQHSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data=Template:Drugs.coma698032Paroxetine DBy mouthPaxil, othersSelective serotonin reuptake inhibitor (SSRI)N06 | _legal_data=S4<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>C1Rx-onlyPOMRx-onlyRx-only

| _other_data=(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine

| _image_0_or_2 = Paroxetine-2D-skeletal.svgParoxetine-from-HCl-xtal-3D-balls.png | _image_LR =

| _datapage = Paroxetine (data page) | _vaccine_target={{#ifeq: | vaccine | | _type_not_vaccine }} | _legal_all=S4C1Rx-onlyPOMRx-onlyRx-only | _ATC_prefix_supplemental=N06 | _has_EMA_link = | CAS_number=61869-08-7 | PubChem=43815 | ChemSpiderID=39888 | ChEBI=7936 | ChEMBL=490 | DrugBank=DB00715 | KEGG=D02362 | _hasInChI_or_Key={{#if:1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1AHOUBRCZNHFOSL-YOEHRIQHSA-N |yes}} | UNII=41VRH5220H | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs={{#invoke:ParameterCount |main |CAS_number2 |ATC_prefix2 |PubChem2 |PubChemStructure2 |IUPHAR_ligand2 |DrugBank2 |ChemSpiderID2 |UNII2 |KEGG2 |ChEBI2 |ChEMBL2 |PDB_ligand2 |NIAID_ChemDB2 |SMILES2 |smiles2 |StdInChI2 |StdInChIKey2 |DTXCID2}} | _countIndexlabels={{#invoke:ParameterCount |main |index_label |index2_label}} | _trackListSortletter= |QID = |QID2 = |Verifiedfields=changed |Watchedfields=changed |verifiedrevid=417832252}}

Paroxetine (Template:IPAc-en Template:Respell), sold under the brand name Paxil among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class<ref name=AHFS2019>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> used to treat major depressive disorder, obsessive–compulsive disorder (OCD), panic disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), generalized anxiety disorder, and premenstrual dysphoric disorder.<ref name=AHFS2019/> It has also been used in the treatment of premature ejaculation, and hot flashes due to menopause.<ref name=AHFS2019/><ref name=FDA2013>Template:Cite press release</ref> It is taken orally (by mouth).<ref name=AHFS2019/>

Common side effects include drowsiness, dry mouth, loss of appetite, sweating, trouble sleeping, and sexual dysfunction.<ref name=AHFS2019/> Serious side effects may include suicidal thoughts in those under the age of 25, serotonin syndrome, and mania.<ref name=AHFS2019/> While the rate of side effects appears similar compared to other SSRIs and SNRIs, antidepressant discontinuation syndrome may occur more often.<ref name="ReferenceD">Template:Cite journal</ref><ref name="ReferenceE">Template:Cite journal</ref> Use in pregnancy is not recommended, while use during breastfeeding is relatively safe.<ref name=Preg2019>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It is believed to work by blocking the reuptake of the chemical serotonin by neurons in the brain.<ref name=AHFS2019/>

Paroxetine was approved for medical use in the United States in 1992 and initially sold by GlaxoSmithKline.<ref name=AHFS2019/><ref>Template:Cite book</ref> It is on the World Health Organization's List of Essential Medicines.<ref name="WHO23rd">Template:Cite book</ref> It is available as a generic medication.<ref name=BNF76>Template:Cite book</ref> In 2022, it was the 92nd most commonly prescribed medication in the United States, with more than 7Template:Nbspmillion prescriptions.<ref name="ClinCalc Top 300">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="ClinCalc Paroxetine">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In 2018, it was in the top 10 of most prescribed antidepressants in the United States.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Medical uses

Paroxetine is primarily used to treat major depressive disorder, obsessive–compulsive disorder, post-traumatic stress disorder, social anxiety disorder, and panic disorder. It is also occasionally used for agoraphobia, generalized anxiety disorder, premenstrual dysphoric disorder, and menopausal hot flashes.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Depression

A variety of meta-analyses have been conducted to evaluate the efficacy of paroxetine in depression. They have variously concluded that paroxetine is superior or equivalent to placebo and that it is equivalent to other antidepressants.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref name="ReferenceF">Template:Cite journal</ref> Despite this, there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any point in time.<ref>Template:Cite journal</ref>

Anxiety disorders

Paroxetine was the first antidepressant approved in the United States for the treatment of panic disorder.<ref>Template:Cite book</ref>Template:Page needed Several studies have concluded that paroxetine is superior to placebo in the treatment of panic disorder.<ref name="ReferenceF"/><ref>Template:Cite journal</ref>

Paroxetine has demonstrated efficacy for the treatment of social anxiety disorder in adults and children.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref> It is also beneficial for people with co-occurring social anxiety disorder and alcohol use disorder.<ref>Template:Cite journal</ref> It appears to be similar to a number of other SSRIs.<ref>Template:Cite journal</ref>

Paroxetine is used in the treatment of obsessive-compulsive disorder.<ref>Template:Cite journal</ref> Comparative efficacy of paroxetine is equivalent to that of clomipramine and venlafaxine.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref> Paroxetine is also effective for children with obsessive-compulsive disorder.<ref>Template:Cite journal</ref>

Paroxetine is approved for the treatment of PTSD in the United States, Japan, and Europe.<ref>Template:Cite journal</ref><ref name=Ip2011>Template:Cite journal</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In the United States, it is approved for short-term use.<ref name=Ip2011/>

Paroxetine is also FDA-approved for generalized anxiety disorder.<ref>Template:Cite journal</ref>

Menopausal hot flashes

In 2013, low-dose paroxetine was approved in the US for the treatment of moderate-to-severe vasomotor symptoms such as hot flashes and night sweats associated with menopause.<ref name=FDA2013/> At the low dose used for menopausal hot flashes, side effects are similar to placebo and dose tapering is not required for discontinuation.<ref name="OrleansLi2014">Template:Cite journal</ref>

Fibromyalgia

Studies have also shown paroxetine "appears to be well-tolerated and improve the overall symptomatology in patients with fibromyalgia", but is less robust in helping with the pain involved.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Adverse effects

Common side effects include drowsiness, dry mouth, loss of appetite, sweating, insomnia, and sexual dysfunction.<ref name="AHFS2019" /> Serious side effects may include suicide in those under the age of 25, serotonin syndrome, and mania.<ref name="AHFS2019" /> While the rate of side effects appears similar compared to other SSRIs and SNRIs, antidepressant discontinuation syndromes may occur more often.<ref name="ReferenceD"/><ref name="ReferenceE"/> Use in pregnancy is not recommended, while use during breastfeeding is relatively safe.<ref name="Preg2019"/>

Paroxetine shares many of the common adverse effects of SSRIs, including (with the corresponding rates seen in people treated with placebo in parentheses):

• nausea 26% (9%)
• diarrhea 12% (8%)
• constipation 14% (9%)
• dry mouth 18% (12%)
• somnolence 23% (9%)
• insomnia 13% (6%)
• headache 18% (17%)
• hypomania 1% (0.3%)
• blurred vision 4% (1%)
• loss of appetite 6% (2%)
• nervousness 5% (3%)
• paraesthesia 4% (2%)
• dizziness 13% (6%)
• asthenia (weakness) 15% (6%)
• tremor 8% (2%)
• sweating 11% (2%)
• sexual dysfunction (≥10% incidence).<ref name = MSR/>

Most of these adverse effects are transient and go away with continued treatment. Central and peripheral 5-HT₃ receptor stimulation is believed to result in the gastrointestinal effects observed with SSRI treatment.<ref name = GG/> Compared to other SSRIs, it has a lower incidence of diarrhea, but a higher incidence of anticholinergic effects (e.g., dry mouth, constipation, blurred vision, etc.), sedation/somnolence/drowsiness, sexual side effects, and weight gain.<ref name="PhDep"/>

Due to reports of adverse withdrawal reactions upon terminating treatment, the Committee for Medicinal Products for Human Use at the European Medicines Agency recommends gradually reducing over several weeks or months if the decision to withdraw is made.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> See also Discontinuation syndrome (withdrawal).

Mania or hypomania may occur in 1% of patients with depression and up to 12% of patients with bipolar disorder.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> This side effect can occur in individuals with no history of mania, but it may be more likely to occur in those with bipolar disorder or with a family history of mania.<ref>Template:Cite journal</ref>

Paroxetine is described as a 'hepatoxic agent'<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> and has been associated with hepatoxicity and jaundice.<ref>Template:Cite journal</ref>

Suicide

Like other antidepressants, paroxetine may increase the risk of suicidal thinking and behaviour in people under the age of 25.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The FDA conducted a statistical analysis of paroxetine clinical trials in children and adolescents in 2004 and found an increase in suicidality and ideation as compared to placebo, which was observed in trials for both depression and anxiety disorders.<ref name=FDA1>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In 2015, a paper published in The BMJ that reanalysed the original case notes argued that in Study 329,<ref name="pmid11437014">Template:Cite journal</ref> assessing paroxetine and imipramine against placebo in adolescents with depression, the incidence of suicidal behavior had been under-reported and the efficacy exaggerated for paroxetine.<ref name="pmid26376805">Template:Cite journal</ref><ref>Template:Cite journal</ref><ref name="pmid26377109">Template:Cite journal</ref><ref name="pmid26377210">Template:Cite journal</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Sexual dysfunction

Template:See also Sexual dysfunction, including loss of libido, anorgasmia, lack of vaginal lubrication, and erectile dysfunction, is one of the most commonly encountered adverse effects of treatment with paroxetine and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is higher than 70%.<ref>Template:Cite journal</ref> Symptoms of sexual dysfunction have been reported to persist after discontinuing SSRIs, although this is thought to be occasional.<ref name=Csoka2008>Template:Cite journal</ref><ref name=Csoka2006>Template:Cite journal</ref><ref>http://pi.lilly.com/us/prozac.pdf Template:Webarchive Page 14.</ref>

Pregnancy

Antidepressant exposure (including paroxetine) is associated with shorter duration of pregnancy (by three days), increased risk of preterm delivery (by 55%), lower birth weight (by Template:Cvt), and lower Apgar scores (by <0.4 points).<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref> The American College of Obstetricians and Gynecologists recommends that for pregnant women and women planning to become pregnant, paroxetine "be avoided, if possible", as it may be associated with increased risk of birth defects.<ref name="Committee2006">Template:Cite journal</ref><ref name=pmid24313569>Template:Cite journal</ref>

Babies born to women who used paroxetine during the first trimester have an increased risk of cardiovascular malformations, primarily ventricular and atrial septal defects. Unless the benefits of paroxetine justify continuing treatment, consideration should be given to stopping or switching to another antidepressant.<ref name="gsk-paxil">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Paroxetine use during pregnancy is associated with about 1.5– to 1.7-fold increase in congenital birth defects, in particular, heart defects, cleft lip and palate, clubbed feet, or any birth defects.<ref name="pmid16926304">Template:Cite journal</ref><ref name="pmid17381382">Template:Cite journal</ref><ref name="pmid17397101">Template:Cite journal</ref><ref name="pmid17688379">Template:Cite journal</ref><ref name="pmid17697910">Template:Cite journal</ref>

Discontinuation syndrome

Template:See also Many psychoactive medications can cause withdrawal symptoms upon discontinuation from administration. Paroxetine has among the highest incidence rates and severity of withdrawal syndrome of any medication of its class.<ref name="pmid25721705">Template:Cite journal</ref> Common withdrawal symptoms for paroxetine include nausea, dizziness, lightheadedness and vertigo; insomnia, nightmares, and vivid dreams; feelings of electricity in the body, as well as rebound depression and anxiety. A liquid formulation of paroxetine is available and allows a very gradual decrease of the dose, which may prevent discontinuation syndrome. Another recommendation is to temporarily switch to fluoxetine, which has a longer half-life and thus decreases the severity of discontinuation syndrome.<ref name="Drug Saf2001-Haddad">Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In 2002, the U.S. FDA published a warning regarding "severe" discontinuation symptoms among those terminating paroxetine treatment, including paraesthesia, nightmares, and dizziness. The agency also warned of case reports describing agitation, sweating, and nausea. In connection with a Glaxo spokesperson's statement that withdrawal reactions occur only in 0.2% of patients and are "mild and short-lived", the International Federation of Pharmaceutical Manufacturers Associations said GSK had breached two of the federation's codes of practice.<ref name="pmid11823353">Template:Cite journal</ref>

Paroxetine prescribing information posted at GlaxoSmithKline has been updated related to the occurrence of a discontinuation syndrome, including serious discontinuation symptoms.<ref name="gsk-paxil"/>

Overdose

Acute overdosage is often manifested by emesis, lethargy, ataxia, tachycardia, and seizures. Plasma, serum, or blood concentrations of paroxetine may be measured to monitor therapeutic administration, confirm a diagnosis of poisoning in hospitalized patients or to aid in the medicolegal investigation of fatalities. Plasma paroxetine concentrations are generally in a range of 40–400 μg/L in persons receiving daily therapeutic doses and 200–2,000 μg/L in poisoned patients. Postmortem blood levels have ranged from 1–4 mg/L in acute lethal overdose situations.<ref>Template:Cite journal</ref><ref>R. Baselt,Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1190–1193.</ref> Along with the other SSRIs, sertraline and fluoxetine, paroxetine is considered a low-risk drug in cases of overdose.<ref>Template:Cite journal</ref>

Interactions

Interactions with other drugs acting on the serotonin system or impairing the metabolism of serotonin may increase the risk of serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reaction. Such reactions have been observed with SNRIs and SSRIs alone, but particularly with concurrent use of triptans, MAO inhibitors, antipsychotics, or other dopamine antagonists.

The prescribing information states that paroxetine should "not be used in combination with an MAOI (including linezolid, an antibiotic which is a reversible non-selective MAOI), or within 14 days of discontinuing treatment with an MAOI", and should not be used in combination with pimozide, thioridazine, tryptophan, or warfarin.<ref name="gsk-paxil"/>

Paroxetine interacts with the following cytochrome P450 enzymes:<ref name = PhDep>Template:Cite book</ref><ref name="ReferenceA">Template:Cite journal</ref>

• CYP2D6 for which it is both a substrate and a potent inhibitor.<ref name = TGA/><ref name="PhDep"/>
• CYP2B6 (strong) inhibitor.
• CYP3A4 (weak) inhibitor.
• CYP1A2 (weak) inhibitor.
• CYP2C9 (weak) inhibitor.
• CYP2C19 (weak) inhibitor.

Paroxetine has been shown to be an inhibitor of G protein-coupled receptor kinase 2 (GRK2).<ref name=":0" /><ref name=":1" />

Pharmacology

File:Paroxetine CYP2D6.png

Mechanism of paroxetine inhibition of CYP2D6<ref name="Metabolism-guided drug design">Template:Cite journal</ref>

Pharmacodynamics

Paroxetine is the most potent and one of the most specific selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRIs).<ref>Template:Cite journal</ref> It also binds to the allosteric site of the serotonin transporter, similarly to escitalopram, though less potently so.<ref>Template:Cite journal</ref> Paroxetine also inhibits the reuptake of norepinephrine to a lesser extent (<50 nmol/L).<ref>Template:Cite journal</ref> Based on evidence from four weeks of administration in rats, the equivalent of 20 mg paroxetine taken once daily occupies approximately 88% of serotonin transporters in the prefrontal cortex.<ref name="ReferenceA"/> Paroxetine is a phenylpiperidine and might have some affinity for opioid receptors.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Binding profile<ref name = GG>Template:Cite book</ref><ref name="ReferenceA"/><ref name="pmid11543737">Template:Cite journal</ref><ref name=PDSP>{{#invoke:citation/CS1|citation

CitationClass=web }}</ref> Paroxetine
Receptor	Ki (nM)
SERT	0.07 – 0.2
NET	40 – 85
DAT	490
D2	7,700
5-HT1A	21,200
5-HT2A	6,300
5-HT2C	9,000
α1	1,000 – 2,700
α2	3,900
M1	72
H1	13,700 – 23,700

Pharmacokinetics

Paroxetine is well-absorbed following oral administration.<ref name="ReferenceA"/> It has an absolute bioavailability of about 50%, with evidence of a saturable first pass effect.<ref name="ReferenceB">Template:Cite journal</ref> When taken orally, it achieves maximum concentration in about 6–10 hours<ref name="ReferenceA"/> and reaches steady-state in 7–14 days.<ref name="ReferenceB"/> Paroxetine exhibits significant interindividual variations in volume of distribution and clearance.<ref name="ReferenceB"/> Less than 2% of an oral dose is excreted in urine unchanged.<ref name="ReferenceB"/>

Paroxetine is a mechanism-based inhibitor of CYP2D6.<ref name="Metabolism-guided drug design"/><ref name="ReferenceC">Template:Cite journal</ref>

File:Paroxetine metabolism.png

Metabolism of paroxetine in humans<ref name="ReferenceC"/>

Society and culture

Paroxetine was approved for medical use in the United States in 1992 and initially sold by GlaxoSmithKline.<ref name="AHFS2019" /><ref>Template:Cite book</ref> It is available as a generic medication.<ref name="BNF76"/> In 2022, it was the 92nd most commonly prescribed medication in the United States, with more than 7Template:Nbspmillion prescriptions.<ref name="ClinCalc Top 300" /><ref name="ClinCalc Paroxetine" /> It is on the World Health Organization's List of Essential Medicines.<ref name="WHO23rd" />

GlaxoSmithKline has paid substantial fines, paid settlements in class-action lawsuits, and become the subject of several highly critical books about its marketing of paroxetine, in particular, the off-label marketing of paroxetine for children, the suppression of negative research results relating to its use in children, and allegations that it failed to warn consumers of substantial withdrawal effects associated with the use of the drug.<ref name="JusticeDept2July2012" /><ref name="USvGSK26Oct2011" />

Marketing

In 2004, GSK agreed to settle charges of consumer fraud for $2.5 million.<ref>Template:Cite news</ref> The legal discovery process also uncovered evidence of deliberate, systematic suppression of unfavorable Paxil research results. One of GSK's internal documents read, "It would be commercially unacceptable to include a statement that efficacy [in children] had not been demonstrated, as this would undermine the profile of paroxetine".<ref>Template:Cite journal</ref>

In 2012, the United States Department of Justice fined GlaxoSmithKline $3 billion for withholding data, unlawfully promoting use in those under 18, and preparing an article that misleadingly reported the effects of paroxetine in adolescents with depression following its clinical trial study 329.<ref name=JusticeDept2July2012>Template:Cite press release</ref><ref name=USvGSK26Oct2011>Template:Cite court</ref><ref name=ThomasNYT2July2012>Template:Cite news</ref>

In February 2016, the UK Competition and Markets Authority imposed record fines of £45 million on companies that were found to have infringed European Union and UK Competition law by entering into agreements to delay the market entry of generic versions of the drug in the UK. GlaxoSmithKline received the bulk of the fines, being fined £37,600,757. Other companies that produce generics were issued fines which collectively total £7,384,146. UK public health services are likely to claim damages for being overcharged in the period where the generic versions of the drug were illegally blocked from the market, as the generics are over 70% less expensive. GlaxoSmithKline may also face actions from other generic manufacturers who incurred losses as a result of the anticompetitive conduct.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In April 2016, appeals were lodged with the Competition Appeal Tribunal by the companies which were fined.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

GSK marketed paroxetine through television advertisements in the 1990s and 2000s. Commercials also aired for the CR version of the drug beginning in 2003.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Economics

In 2007, paroxetine was ranked 94th on the list of bestselling drugs, with over $1 billion in sales. In 2006, paroxetine was the fifth-most prescribed antidepressant in the U.S. retail market, with more than 19.7 million prescriptions.<ref>The paroxetine prescriptions were calculated as a total of prescriptions for Paxil CR and generic paroxetine using data from the charts for generic and brand-name drugs.{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In 2007, sales had dropped slightly to 18.1 million but paroxetine remained the fifth-most prescribed antidepressant in the U.S.<ref>The paroxetine prescriptions were calculated as a total of prescriptions for Paxil CR and generic paroxetine using data from the charts for generic and brand-name drugs.{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Brand names

Brand names include Aropax, Paretin, Brisdelle, Deroxat, Paxil,<ref name="Nevels2016">Template:Cite journal</ref><ref>Template:Cite book</ref> Pexeva, Paxtine, Paxetin, Paroxat, Paraxyl,<ref>Template:Cite book</ref> Sereupin, Daparox and Seroxat.

Research

Several studies have suggested that paroxetine can be used in the treatment of premature ejaculation. In particular, intravaginal ejaculation latency time (IELT) was found to increase 6- to 13-fold, which was somewhat longer than the delay achieved by the treatment with other SSRIs (fluvoxamine, fluoxetine, sertraline, and citalopram).<ref name="pmid9690692">Template:Cite journal</ref><ref name="pmid11763001">Template:Cite journal</ref><ref name="pmid15363569">Template:Cite journal</ref> However, paroxetine taken acutely ("on demand") 3–10 hours before coitus resulted only in a "clinically irrelevant and sexually unsatisfactory" 1.5-fold delay of ejaculation and was inferior to clomipramine, which induced a fourfold delay.<ref name="pmid15363569"/>

There is also evidence that paroxetine may be effective in the treatment of compulsive gambling<ref>Template:Cite journal</ref> and hot flashes.<ref>Template:Cite journal</ref>

Benefits of paroxetine prescription for diabetic neuropathy<ref>Template:Cite journal</ref> or chronic tension headache<ref name="pmid8132436">Template:Cite journal</ref> are uncertain.

Although the evidence is conflicting, paroxetine may be effective for the treatment of dysthymia, a chronic disorder involving depressive symptoms for most days of the year.<ref name="pmid19017592">Template:Cite journal</ref>

There is evidence to support that paroxetine selectively binds to and inhibits G protein-coupled receptor kinase 2 (GRK2) in mice with heart failure. Since GRK2 regulates the activity of the beta adrenergic receptor, which becomes desensitized in cases of heart failure, paroxetine (or a paroxetine derivative) could be used as a heart failure treatment in the future.<ref name=":0">Template:Cite journal</ref><ref name=":1">Template:Cite journal</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Paroxetine has been identified as a potential disease-modifying osteoarthritis drug.<ref>Template:Cite journal</ref>

Veterinary use

Paroxetine may be useful in the treatment of canine or feline behavioral diagnoses and is effective in the treatment of social anxiety, depression, and agitation associated with depression.<ref>Template:Cite journal</ref>

Other organisms

Paroxetine is a common finding in wastewater.<ref name="Runoff" /> It is highly toxic to the alga Pseudokirchneriella subcapitata (syn. Raphidocelis subcapitata).<ref name="Runoff">

  Template:Unbulleted list citebundle

</ref>

It also is toxic to the soil nematode Caenorhabditis elegans.<ref name="Repurposing">

  Template:Unbulleted list citebundle

</ref>

Alberca et al., 2016 found that paroxetine acts as a trypanocide against T. cruzi.<ref name="Chagas"> Template:Cite journal

This review cites this study.

Template:Cite journal </ref>

Alberca et al., 2016 finds a leishmanicide effect.<ref name="computerguided"/> Alberca finds that paroxetine produces cell death of the promastigotes of L. infantum.<ref name="computerguided"/> The mechanism of action remains unknown.<ref name="computerguided">

This review cites this research.

</ref>

Various types of bacteria can break down paroxetine in the environment. These include, for example Pseudomonas sp., Bosea sp., Shewanella sp., Species of Chitinophagaceae and Acinetobacter sp.<ref>Template:Cite book</ref><ref>Template:Cite journal</ref>

External links

• Template:Commons category-inline

Template:Navbox with collapsible groups {{#invoke:navbox|navbox | name = Anxiolytics | title = Anxiolytics (N05B) | state = collapsed | groupstyle = text-align:center; | listclass = hlist

 | group1 = Template:Abbrlink agonists
 |  list1 =

• Buspirone
• Gepirone
• Tandospirone

 | group2 = Template:Abbrlink Template:Abbrlink
 |  list2 = 

• Benzodiazepines: Adinazolam
• Alprazolam
• Bromazepam
• Camazepam
• Chlordiazepoxide
• Clobazam
• Clonazepam
• Clorazepate
• Clotiazepam
• Cloxazolam
• Diazepam^#
• Ethyl loflazepate
• Etizolam
• Fludiazepam
• Halazepam
• Ketazolam
• Lorazepam^#
• Medazepam
• Nordazepam
• Oxazepam
• Pinazepam
• Prazepam; Others: Alpidem^‡
• Barbiturates (e.g., phenobarbital)
• Carbamates (e.g., meprobamate)
• Carisoprodol
• Chlormezanone^‡
• Ethanol (alcohol)
• Etifoxine

 | group3 = Hypnotics
 | list3 =

• Zopiclone

 | group4 = Gabapentinoids
([[Voltage-dependent calcium channel#.CE.B12.CE.B4_Subunit|Template:Abbr Template:Abbr]] blockers)
 |  list4 =

• Gabapentin
• Gabapentin enacarbil
• Phenibut
• Pregabalin

 | group5 = Antidepressants
 | list5 = 

• Template:Abbrlink (e.g., escitalopram)
• Template:Abbrlink (e.g., duloxetine)
• Template:Abbrlink (e.g., trazodone)
• Template:Abbrlink (e.g., clomipramine^#)
• Template:Abbrlink (e.g., mirtazapine)
• Template:Abbrlink (e.g., phenelzine); Others: Agomelatine
• Bupropion
• Tianeptine
• Vilazodone
• Vortioxetine

 | group6 = Antipsychotics
 | list6 =

• Quetiapine
• Flupentixol

 | group7 = Sympatholytics
(Antiadrenergics)
 |  list7 =

• Alpha-1 blockers (e.g., prazosin)
• Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine)
• Beta blockers (e.g., propranolol)

 | group8 = Others
 |  list8 =

• Benzoctamine
• Cycloserine
• Fabomotizole
• Hydroxyzine
• Lorpiprazole
• Mebicar
• Mepiprazole
• Nicotine
• Opipramol
• Oxaflozane^‡
• Phenaglycodol
• Phenibut
• Picamilon
• Selank
• Tiagabine
• Tofisopam
• Validolum

| list9 = Template:PharmNavFootnote

}} Template:OCD pharmacotherapies Template:Monoamine reuptake inhibitors Template:Muscarinic acetylcholine receptor modulators Template:GlaxoSmithKline Template:Portal bar